Patients with Advanced Triple Negative Breast Cancer

Status: open

17-147 - A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

Treatment for Breast Cancer

Contact Us Or call (251) 445-9834


CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in patients of African ancestry and non-African ancestry with advanced triple negative breast cancer. Multiple single-arm cohorts will be enrolled in which 800 mg BID CB-839 will be administered in combination with the full approved dose of paclitaxel. IRB Number 17-147


This trial is sponsored by Calithera.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.